期刊文献+

芳香化酶抑制剂对卵巢癌组织块体外培养活性的影响 被引量:1

Effects of Aromatase Inhibitors on the Activity of Ovarian Cancer Histocultur
下载PDF
导出
摘要 目的建立卵巢癌组织块体外培养模型,探讨芳香化酶抑制剂(aromatase inhibitors,AIs)来曲唑对卵巢癌组织块体外培养活性的影响。方法选取卵巢浆液性囊腺癌组织块进行体外培养,加入不同浓度的来曲唑观察肿瘤细胞坏死情况。采用免疫组织化学方法,检测标本中芳香化酶P450及雌激素受体的表达。结果建立卵巢癌组织块体外培养模型,并在6例标本中筛选出AIs敏感病例及部分敏感病例各1例。敏感及部分敏感病例芳香化酶P450及雌激素受体的表达水平均与不敏感病例无明显差别。结论卵巢癌组织块体外培养,为卵巢癌的体外药敏试验提供了一个良好的研究模型,来曲唑对部分卵巢癌肿瘤组织有抑制作用。 Objective To establish ovarian cancer histoculture model and explore the effects of aromatase inhibitor letrozole on the activity of ovarian cancer histoculture.Methods Histoculture of ovarian serous cystadenoma join in different levels of letrozole to observe the tumor cells necrosis rate changes.Immunohistochemistry staining was used to check the presence and the features of aromatase and estrogen receptor of specimens.Results Establish ovarian cancer histoculture model,filter out a sensitive case and a partly sensitive case to aromatase inhibitors in 6 cases.The expression of aromatase and estrogen receptor in the two cases were no obvious difference.Conclusion ovarian cancer histoculture is a good mode of ovarian cancer chemosensitivity assay.Letrozole is a inhibition for some cases of ovarian cancer.
作者 周璘 苏亦平
出处 《实用癌症杂志》 2012年第2期123-125,共3页 The Practical Journal of Cancer
基金 南京市医学科技发展基金资助(YKK08113)
关键词 卵巢癌 体外培养 芳香化酶抑制剂 Ovarian cancer Histoculture Aromatase inhibitors
  • 相关文献

参考文献1

二级参考文献17

  • 1刘爱芹,卢霞,于胜海.抗癌新药来曲唑的临床进展及市场展望[J].齐鲁药事,2004,23(5):37-38. 被引量:10
  • 2祝鸿,徐进宜,吴晓明.芳香化酶抑制剂来曲唑的研究进展[J].海峡药学,2004,16(4):1-5. 被引量:8
  • 3鞠瑞秀,丁玉峰,王慎田.新型芳香化酶抑制剂在乳腺癌中的应用[J].医学综述,2004,10(12):721-722. 被引量:2
  • 4Mouridsen H,Gershanovich M,Sun Y,et al.Superior efficacy of L-etrozole (Femara) versus Tamoxifen as first-line therapy for postmanopausal women with advanced breast cancer:results of a phase III study of the international Letrozole Breast Cancer Group[J].J Clinical Oncology,2001,19(10):2596.
  • 5A,Lipton,S M Ali,K Leitzel.Serum HER-2/neu and response to the aromatase inhibitor letrozole versus tamoxifen[J].Journal of Clinical Oncology,2003,21(10):1967.
  • 6Henning Mouridsen,Mikhail Gershanovich,Yan sun,et al.Superior efficacy of letrozole versus tamoxifen as first-line therapy for postmenopausal women with advanced breast cancer:results of a phase III study of the international letrozole breast cancer group[J].Jouranal of Clinical Oncology,2001,19(10):2596.
  • 7A Buzdar J Douma,N Davidson.Phase III,multicenter,double-blind,randomized study of letrozole,an aromatase inhibitor,for advanced breast cancer versus megestrol acetate[J].Journal of Clinical Oncology,2001,119 (1):3357.
  • 8Matthew J,Ellis,Andrew Coop,et al.Letrozole is more effective neoadjuvant endocrine therapy than tamoxifen for ErbB-1and/orErbB-2-positive,Estrogen receptor-positive primary breast cancer:Evidence from a phase III randomized trial[J].Journal of Clinical Oncology,2001,19(18):3808.
  • 9Paul E,James N,Silvana Martino,et al.A randomized trial of letrozole in postmenopausal women after five years of tamoxifen therapy for early-stage breast cancer[J].The New England Journal of Medicine,2003,349(19):1793.
  • 10Henning Mouridsen,Mikhail Gershanovich,Yan Sun,et al.Phase III study of letrozole versus tamozifen as first-line therapy of advanced breast cancer in postmenopausal women:Analysis of survival and update of efficacy from the international letrozole breast cancer group[J].Journal of Clinical Oncology,2003,21(11):2101.

共引文献5

同被引文献3

引证文献1

二级引证文献10

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部